You are here

Inhaling gaseous vinyl chloride

Document

Soft tissue sarcoma - Inhaling gaseous vinyl chloride Factor

Last reviewed for CCPS 20 August 2008.

Investigative Documents

Claimant Report - Inhaling Gaseous Vinyl Chloride [CR9090]

Preliminary questions [22777]

22859

there is some evidence that inhaling gaseous vinyl chloride may be a factor in the development of the condition under consideration.

22781the veteran has established the causal connection between inhaling gaseous vinyl chloride and VEA service for the clinical onset of soft tissue sarcoma.

22782the veteran has established the causal connection between inhaling gaseous vinyl chloride and operational service for the clinical onset of soft tissue sarcoma.

or

22783the veteran has established the causal connection between inhaling gaseous vinyl chloride and eligible service for the clinical onset of soft tissue sarcoma.

Clinical onset and operational service [22782]

27347 the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at some time.

22785

the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least two years before the clinical onset of the condition under consideration.

22779

operational service made a material contribution to the veteran inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least two years before the clinical onset of the condition under consideration.

Clinical onset and eligible service [22783]

22778

the condition under consideration is an hepatic angiosarcoma.

27347

the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at some time.

22788

the veteran inhaled a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least five years before the clinical onset of the condition under consideration.

22787

eligible service made a material contribution to the veteran inhaling a cumulative dose of at least 200 ppm-years of gaseous vinyl chloride at least five years before the clinical onset of the condition under consideration.